ITCI Intra-Cellular Therapies Inc.

13.55
-0.76  -5%
Previous Close 14.31
Open 14.21
Price To Book 2.1
Market Cap 741541785
Shares 54,726,331
Volume 394,710
Short Ratio
Av. Daily Volume 378,975

SEC filingsSee all SEC filings

  1. 8-K - Current report 181229998
  2. 8-K - Current report 181227787
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166784
  4. 8-K - Current report 181164695
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988563

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis due 4Q 2018.
ITI-007-201
Agitation in patients with dementia
PDUFA date September 27, 2019.
Lumateperone
Schizophrenia
Phase 3 enrollment to be completed 2H 2018.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)

Latest News

  1. Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology
  2. Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
  3. Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT
  4. Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta?
  5. Intra-Cellular: 3Q Earnings Snapshot
  6. Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results
  7. Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast
  8. Investor Expectations to Drive Momentum within Tribune Media, Intra-Cellular Therapies, Icahn Enterprises, NVE, PetMed Express, and United Fire Group — Discovering Underlying Factors of Influence
  9. Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
  10. Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting
  11. Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer
  12. Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?
  13. Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock
  14. Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
  15. Intra-Cellular Therapies to Present at the Cantor Fitzgerald Global Healthcare Conference
  16. Is Intra-Cellular Therapies Inc (NASDAQ:ITCI) A Financially Sound Company?

SEC Filings

  1. 8-K - Current report 181229998
  2. 8-K - Current report 181227787
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166784
  4. 8-K - Current report 181164695
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988563
  6. 8-K - Current report 18986647
  7. S-8 - Securities to be offered to employees in employee benefit plans 18912540
  8. 8-K - Current report 18912140
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18803774
  10. 8-K - Current report 18801784